Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Citi
Queensland Health
Healthtrust
Deloitte
Julphar
Teva
Harvard Business School
Boehringer Ingelheim

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 200153

« Back to Dashboard

NDA 200153 describes LIPTRUZET, which is a drug marketed by Merck Sharp Dohme and is included in one NDA. Additional details are available on the LIPTRUZET profile page.

The generic ingredient in LIPTRUZET is atorvastatin calcium; ezetimibe. There are sixty-one drug master file entries for this compound. Additional details are available on the atorvastatin calcium; ezetimibe profile page.
Summary for 200153
Tradename:LIPTRUZET
Applicant:Merck Sharp Dohme
Ingredient:atorvastatin calcium; ezetimibe
Patents:0
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrengthEQ 10MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:May 3, 2013TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrengthEQ 20MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:May 3, 2013TE:RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrengthEQ 40MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:May 3, 2013TE:RLD:Yes

Expired US Patents for NDA 200153

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-001 May 3, 2013 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-004 May 3, 2013 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-002 May 3, 2013 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-002 May 3, 2013 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Citi
McKinsey
Medtronic
Julphar
Fish and Richardson
Express Scripts
Dow
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.